Pipeline Overview

Click to learn about the trilaciclib mechanism of action

G1 is advancing a pipeline of three investigational therapies with the potential to improve outcomes in multiple oncology indications.

We have exclusive worldwide development and commercialization rights to trilaciclib, rintodestrant (G1T48) and lerociclib, with more than 115 U.S. and international patents and pending patent applications covering our development programs.